anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults with cocaine use disorder will be randomly assigned to experimental or control groups, stratified by polydrug use disorder, SES, and sex. The experimental group will compare episodic future thinking (EFT) to control episodic thinking (CET). The study procedures will include a baseline session (S1) and a 4-week intervention period where participants will return to the lab three times a week. Participants will generate new EFT and CET events at approximately weekly intervals. The EFT or CET events will be texted to them twice daily with urine samples obtained thrice-weekly. To probe resistance to disruption, both groups will receive stress-inducing probes that shorten the temporal window after the first and last cue generation. During the first assessment visit (S2), participants will be randomized with stratification to generate either episodic future thinking (EFT) or control episodic thinking (CET) events and will undergo neuroimaging procedures. At the following session in S3, participants will be randomized to receive one of two stress probes (counterbalanced) or their respective control. Participants will be exposed to a stress probe or control at S3 and the corresponding narrative at the next visit, S4. S5 and S6 will begin with participants generating new EFT/CET events that will be used for that session and the following two sessions. S7, like S2, will begin with EFT/CET event generation and neuroimaging procedures. During the final two sessions (S8, S9), participants will be exposed to the other stress probe and control that they did not see during S3/S4.
Dosage should be individualized to obtain an adequate response with the lowest effective dose.

The usual adult dose is one tablet (37.5 mg) daily, as prescribed by the physician, administered before breakfast or 1 to 2 hours after breakfast. The dosage may be adjusted to the patient's need. For some patients, half tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give half tablets (18.75 mg) two times a day.

Phentermine is not recommended for use in pediatric patients ≤ 16 years of age.

Late evening medication should be avoided because of the possibility of resulting insomnia.
To provide an information processing device and a program that can easily confirm past diagnosis results even when an organization to which a person to be examined belongs has changed.SOLUTION: An information processing device provides diagnostic information and includes a management section, an acceptance section, a specification section, and a provision section. The management section manages first identification information and second identification information. The first identification information is identification information issued by a first organization, and the second identification information is identification information issued by a second organization. The acceptance section accepts a command to associate the first identification information and the second identification information. The specification section associates the first identification information and the second identification information managed by the management section on the basis of the command accepted by the acceptance section. When the first identification information and the second identification information are associated, the provision section provides diagnostic information corresponding to the first identification information and diagnostic information corresponding to the second identification information to a user identified by the first identification information and a user identified by the second identification information.SELECTED DRAWING: Figure 3
PURPOSE: To obtain an antimicrobial cosmetic pigment continuously having uniform antimicrobial and antiseptic effects for a long time without stimulating skin. CONSTITUTION: This antimicrobial cosmetic pigment comprises an inorganic pigment, the complex coating layer of an amorphous glassy metal oxide formed on the surface of the inorganic pigment and a solid solution of antimicrobial metals (silver, copper, zinc are preferable) or antimicrobial metal ions intercalated inside the lattice structure of the coating layer. The metal oxides for forming the coating layer include silica or silica and one or more oxides selected from the group consisting of zinc oxide, magnesium oxide, calcium oxide, aluminum oxide, lithium oxide, sodium oxide, potassium oxide and iron oxide. The amount of the coating is 3.0-50.0 pts.wt. based on 100 pts.wt. of the coating layer. The amount of the antimicrobial metals to be mixed is 0.00001-5.0 pts.wt., especially 0.01-1.0 pts.wt. based on 100 pts.wt. of the coating layer.  The pigment is added to the composition in 0.001-50.0 wt.%, especially in 0.1-20.0 wt.%.
Achilles tendinopathy is a debilitating injury that is common among athletes, especially those involved in running sports. Around 30% of all runners exhibit Achilles tendinopathy with an annual incidence of 7-9%. Of these patients, roughly one-third will have insertional Achilles tendinopathy (IAT). Several mechanisms are considered to play a role in the aetiology of Achilles tendinopathy, yet a prominent role seems present for excessive overload. Traditionally, the nature of this overload is thought to be purely tensile. However, the Achilles tendon can also be exposed to compressive loads at the insertion when the tendon wraps around the posterior prominence of the calcaneus during dorsiflexion of the ankle. The formation of fibrocartilage-like tissue, which is typically found in histological examination of tendinopathy, can be considered as an adaptation to this compressive load, driven by the tenocyte's mechanotransduction process. Therefore, it is recommended to reduce the amount of compressive load on the tendon during rehabilitation while exerting sufficient tensile load. However, these recommendations are mainly based on a pilot study and expert opinion. Therefore, this RCT investigates whether a therapy in which the amount of tendon compression is restricted during a progressive tendon-loading rehabilitation protocol actually has better outcomes in terms of pain scores, functionality and structure of the Achilles tendon in athletes with insertional Achilles tendinopathy. Limiting the amount of tendon compression on the Achilles tendon insertion will be achieved by (1) patient education, (2) heel inserts and (3) an adapted exercise regimen.
In Japan, brain docking has enhanced the detection of unruptured intracranial aneurysms in healthy adults. At our institution, surgical clipping is the first-line treatment for unruptured intracranial aneurysms (UIA). In this study, the differences in neurological and radiological outcomes, as well as cognitive and psychological results, between standard clipping and keyhole clipping for these aneurysms detected via brain docking were evaluated. The study included 131 aneurysms detected via "brain dock." Of these, 65 were treated with keyhole clipping surgery (keyhole clipping group), and 66 were treated with standard clipping surgery (standard clipping group). Evaluations at 3 months included the National Institutes of Health Stroke Scale, modified Rankin Scale, Mini-Mental State Examination, Hasegawa's Dementia Scale-revised, Beck Depression Inventory, Hamilton Rating Scale for Depression, and radiological abnormalities. The mean operative time and postoperative hospitalization period were significantly shorter in the keyhole clipping group than in the standard clipping group (p < 0.001). Between the groups, no significant differences in postoperative neurological complications or radiological abnormalities were found. The keyhole clipping group demonstrated slightly but significantly better Beck Depression Inventory and Hamilton Rating Scale for Depression scores than the standard clipping group (Beck Depression Inventory, p = 0.046; Hamilton Rating Scale for Depression, p < 0.01). Both the Beck Depression Inventory and Hamilton Rating Scale for Depression scores at 3 months were significantly enhanced (p < 0.001) in the keyhole clipping group. These findings propose that keyhole clipping could be considered a new therapeutic option for small UIA detected via brain docking.
This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
This study will evaluate changes in drinking identity and changes in drinking during the transition out of high school in a sample of 528 soon-to-graduate high school seniors via the future possible self task (FPST). We will test whether an adapted version of the FPST can induce change in drinking identity and reduce risk of alcohol misuse. The study will have a 2 (write about future desired self in relation to drinking vs. no), x 2 (write about future feared self in relation to drinking vs. no) x 2 (write 1x only vs.1x per week for 3 weeks) design. Participants will be randomly assigned to a condition. The study will occur entirely online, with virtual baseline and intervention sessions hosted by a research assistant and with online surveys for the 1-, 3-, 6-, and 12-month follow-ups. Participants, who report at least some alcohol consumption and some interest interest in changing or not increasing their drinking, will be recruited, in equal numbers, from two sites -- one at the University of Washington and one at the University of Houston. Participants will be recruited in two waves (264 each wave, with 132 from each site during each wave).

The study will test for changes in drinking identity (primary), in indicators of alcohol misuse (primary \& secondary), and in associated risk factors (secondary; changes in self-efficacy, identification with future self, and craving at baseline, 1-, 3-, 6-, and 12-month follow-ups
The article presents data on the relationship of pathogenetic mechanisms for the development of menstrual disorders of functional and organic origin in connection with mental disturbances from the point of view of the psychosomatic concept. According to the latter, functional disorders of the menstrual cycle are considered as psychosomatic, in which gynecological pathology develops as a result of psychopathological illness. A striking example of such a disorder is functional hypothalamic amenorrhea. At the same time, endocrinopathies, such as polycystic ovary syndrome and premature ovarian insufficiency, can also be considered in the paradigm of psychosomatic illnesses of ovarian function due to the high prevalence of anxiety and depressive disorders in this cohort of patients. This review highlights the importance of interdisciplinary collaboration between a gynecologist and a psychiatrist for the most effective reproductive rehabilitation of patients with amenorrhea. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full text of articles. The choice of sources was prioritized for the period from 2018 to 2023.However, taking into account the insufficient knowledge of the chosen topic, the choice of sources dates back to 1985.
Niraparib is a FDA approved Poly(ADP-ribose) polymerase inhibitor (PARPi) for the treatment of platinum-sensitive ovarian serous carcinoma. The safety profile of niraparib was established in phase III clinical trials. The therapeutic effect of niraparib on serous endometrial carcinoma is now being investigated in several clinical trials. However, the antineoplastic effect and the safety profile of niraparib in chemotherapy naïve high-grade endometrial cancer patients is unknown. By employing a phase 0 exploratory trial design, the investigators will study the niraparib's effect on endometrial cancer in chemotherapy naïve patients using molecular biomarkers as sentinels for the antineoplastic effect. Women diagnosed by endometrial biopsy with high-grade endometrial cancer will receive niraparib for 28 days. Staging surgery will be performed 4-6 weeks after the diagnosis (standard of care). The investigators will use the pre-operative biopsy and the surgical specimen to perform comparative multidimensional analysis of endometrial tumors before and after exposure to niraparib.
Endocannabinoid system plays a pivotal role in controlling neuroinflammation, and modulating this system may not only aid in managing symptoms of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Multiple sclerosis, Epilepsy, Central and Peripheral neuropathic pain, but also, have the potential to target these diseases at an early-stage. In the present study, six different pharmacophore hypotheses were generated from Cannabidiol (CBD)-Cannabinoid Receptor subtype-2 (CB2) and then Zinc database was screened for identification of hit molecules. Identified 215 hit molecules were subjected to preliminary screening with ADMET and drug likeness properties, and about 48 molecules were found with no violations and toxicity properties. In molecular docking studies, six compounds showed better binding energy than CBD and β-caryophyllene (known inhibitor of CB2). These six molecules were designated as leads and subjected to re-docking with glide tool and Lead1 (ZINC000078815430) showed docking score of -9.877 kcal/mol, whereas CBD and β-caryophyllene showed score of -9.664 and -8.499 kcal/mol, respectively. Lead1 and CBD were evaluated for stability studies with Desmond tool by molecular dynamic simulation studies. Lead1 showed better stability than CBD in all studied parameters such as RMSD, RMSF, SSE, Rg, SASA, etc. In MM-GBSA free energy calculations, ΔGbinding energy of CB2-CBD complex and CB2-Lead1 were found to be -103.13±11.19 and -107.94±5.42 kcal/mol, respectively. Six lead molecules stated in the study hold promise with respect to CBD agonistic activity for treating and/or managing chronic conditions and can be explored as an alternative for early-stage cure, which has not yet been experimentally explored.
PCT No. PCT/FR95/01294 Sec. 371 Date Oct. 21, 1996 Sec. 102(e) Date Oct. 21, 1996 PCT Filed Oct. 5, 1995 PCT Pub. No. WO96/10987 PCT Pub. Date Apr. 18, 1996Its subject is more specifically a process for making suppositories releasing carbon dioxide and endowed with a laxative action in which the fatty substances are melted separately and vegetable lecithin is added into the fluid mass resulting from the melting and then a mineral opacifying agent is incorporated, followed by the pouring of potassium acid tartrate and sodium bicarbonate accompanied by stirring, these two constituents having a particular granulometry, and stirring is then continued until perfect homogeneity is achieved before proceeding with the drawing-off of the fluid suspension.
Depo-subQ provera 104 is indicated for the prevention of pregnancy and management of endometriosis-associated pain in females of reproductive age. Efficacy is expected to be the same for post-menarchal females under the age of 17 as for users 17 years and older.

Use of depo-subQ provera 104 is associated with significant loss of bone mineral density (BMD). This loss of BMD is of particular concern during adolescence, a critical period of bone accretion. It is unknown if use of depo-subQ provera 104 by female adolescents will reduce peak bone mass and increase the risk for osteoporotic fractures in later life. In a study of adolescent females (12–18 years of age) receiving DMPA-IM for contraception, mean BMD 2 years after starting DMPA-IM decreased 1.9% (spine), 4.3% (total hip), and 4.2% (femoral neck). In those adolescents who used DMPA-IM for more than 2 years, mean BMD at total hip and femoral neck did not return to baseline within 5 years.

Depo-subQ provera 104 is not indicated before menarche.
Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
<P>PROBLEM TO BE SOLVED: To obtain a cleansing cosmetic which exhibits a transparent liquid state, has excellent cleansing power and causes neither reduction in cleansing power nor deterioration of appearance and sense of use even in the case of application to the wet skin.  <P>SOLUTION: The transparent liquid cleansing cosmetic is a composition comprising (A) a 12-18C fatty acid residue-containing monoglycerol fatty acid ester, (B) a 12-18C fatty acid residue-containing polyglycerol fatty acid ester, (C) a water-soluble nonionic surfactant except the component (A) and the component (C), (D) an oily component liquid at 25°C and (E) 1-12 wt.% of water in the weight ratio of the component A: the component (B) of 20:80-80:20 and causes no white turbidity when 50 parts wt. of water is added to 100 parts wt. of the composition. The cleansing cosmetic has excellent sense of use and excellent storage stability at a low temperature, is usable for the skin wet with water and is suitably useful especially in a bathroom.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:A hypertension preventive that contains, as an active ingredient, a high-molecular-weight substance which is obtained by removing cell bodies and casein from fermented milk, thus being a labor-saving product with good hypotensive action without side-effects. CONSTITUTION:Cell bodies and casein are removed from fermented milk to give a substance of 5,000 or more molecular weight and it is used as a hypotensor. The fermented milk is produced by fermentation of animal or soybean milk with a lactobacillus or a combination thereof with yeast until the count of cell bodies reaches over 10<7>/ml. The resultant fermented milk is adjusted in its pH nearly to the isoelectric point of casein to effect the precipitation of casein, then filtration is carried out to remove casein and cell bodies. The supernatant is subjected to ultrafiltration, then dialysis to collect the fraction corresponding to 5,000 or more molecular weight. The resultant fraction or its processed products are used as a medicine or health food.
Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6" x 5" x 1") and lightweight (8 oz.) box.
Each participant will benefit from a medical interview before inclusion to eliminate the contraindications to this study. The maximum duration of the individual participation of each subject in this study is 5 hours in two sessions. Each session lasts 2h30. Both sessions are spaced a maximum of 14 days apart. Each session includes EEG headset placement and oculometer calibration (20 min), followed by recording EEG and eye tracking activity during a visual cognitive task where the participant will be presented with multi-stable visual stimuli to watch. for one or two minutes after the tests. By repeating the essays and the conditions of presentation, each session will be organized in six blocks of 20 minutes each, interspersed with a break.
Orally administrable medicament for the treatment of cerebral function deficiencies, such as trisomia 21 (mongolism) or Alzheimer's dieseas (presenile sclerosis) and more generally mental debility, comprises L-serine or glycine. L-serine or glycine is administered orally in unit doses of 50-1000 mg. pref. 250 mg. They may be administered as liqs. eg. as ampoules or syrups or as solids eg. as gelules or tablets.
BACKGROUND: In order to improve perioperative pain and reduce the adverse outcome of severe pain in elderly hip fractures, anterior iliopsoas muscle space block (AIMSB) can be used clinically to reduce pain. The aim of the study is to investigate the 50% effective concentration (EC50) of ropivacaine for ultrasound-guided anterior iliopsoas space block in elderly with hip fracture.
METHODS: A total of 27 patients were enrolled with aged ≥65 years, American society of Anesthesiologists (ASA) physical status classification II-III and undergoing Total Hip Arthroplasty (THA). We measured the EC50 using Dixon's up-and-down method. Ultrasound-guided AIMSB was performed preoperatively with an initial concentration of 0.2% in the first patient. After a successful or unsuccessful postoperative analgesia, the concentration of local anesthetic was decreased or increased 0.05%, respectively in the next patient. The successful block effect was defined as no sensation to pinprick in the area with femoral nerve, obturator nerve, and lateral femoral cutaneous nerve in 30 min. Meanwhile, the EC50 of ropivacaine was determined by using linear model, linear-logarithmic model, probit regression model, and centered isotonic regression.
RESULTS: A total of 12 patients (48%) had a successful block. All patients with a successful block had a postoperative visual analog scale score of <4 in the 12 h. The estimated EC50 values in linear model, linear-logarithmic model, probit regression model, and centered isotonic regression (a nonparametric method) were 0.268%, 0.259%, 0.277%, and 0.289%. The residual standard error of linear model was the smallest (0.1245).
CONCLUSION: The EC50 of ropivacaine in anterior iliopsoas space block under ultrasound guidance is 0.259-0.289%.
Provided are a tumor-specific polypeptide sequence and an application thereof. The polypeptide comprises at least any polypeptide in a first peptide group, and can optionally comprise at least any polypeptide in a second peptide group. The first peptide group comprises polypeptides having the sequences shown in SEQ ID NO: 1 to SEQ ID NO: 5; the second peptide group comprises derived peptides having the sequences shown in SEQ ID NO: 1 to SEQ ID NO: 5. The derived peptides comprise front, middle and back peptide segments connected in sequence. The middle peptide segment has at least 80% homology with the sequences shown in SEQ ID NO:1 to SEQ ID NO:5, and the sum of the lengths of the front and back peptide segments is 14-16 amino acids. Also provided are an isolated nucleic acid, a construct, an expression vector, a pharmaceutical composition, an antigen presenting cell, an immune effector cell, a tumor vaccine, and use of the polypeptide in the preparation of a drug for preventing or treating a tumor and a method for treating a tumor patient.
This study aimed at assessing the effects of two infra-vitam traits, specifically the slaughter weight (SW) and the ultrasound backfat depth (BCKF) on several post-mortem and quality traits of typical Prosciutto Veneto protected designation of origin (PDO) dry-cured ham. The trial was conducted on a population of 423 pigs fed using different strategies to generate a high variation in SW (175 ± 15.5 kg) and BCKF (23.16 ± 4.14 mm). All the left thighs were weighed at slaughter and the ham factory during the different processing phases. The fat cover depth of green trimmed hams was measured. Data were analyzed with a linear model including SW classified in tertiles, BCKF as a covariate, SW × BCKF interaction, sex, batch, and pen nested within batch. Our results highlighted that, for each 10 kg increase in SW, trimmed and seasoned ham weights increased by 0.76 and 0.54 kg, respectively. The increase in SW significantly reduced relative curing and deboning losses but did not affect ham fat cover depth and trimming losses. A rise in BCKF increased the ham fat cover depth and trimming losses and decreased the curing and deboning losses. Increases in SW and BCKF improved quality traits of the seasoned ham including fat cover depth, visible marbling, inner lean firmness, and fat color. These findings confirm the feasibility of increasing SW and BCKF, which will result in a reduction in the relative losses associated with the dry-curing process while improving the quality of the seasoned ham.